<DOC>
	<DOCNO>NCT02252783</DOCNO>
	<brief_summary>BFPET evaluate diagnostic PET agent assess myocardial perfusion subject know suspected coronary artery disease ( CAD ) compare standard nuclear myocardial perfusion imaging ( MPI ) . The safety BFPET evaluate know suspected CAD subject .</brief_summary>
	<brief_title>BFPET Regional Myocardial Perfusion Imaging</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Subjects must provide write informed consent prior study related procedure ; Subjects must ≥ 21 ≤ 85 year age ; Subjects must know suspected CAD document ≥2 segment reversible perfusion abnormality SPECT ( MPI ) study Exclusion Criteria Any clinically significant acute unstable physical psychological disease judge investigator base medical history screen physical examination ; Blood pressure 180/100mmHg Acute change comparison recent ECG ; Recent ( within 3 month ) cardiac arrest , unstable angina , cerebrovascular accident ( CVA ) , CABG PCI Any pacemaker defibrillator implant within last three month ; Inability remain camera approximately 60 minute Bronchospasm Serum creatinine &gt; 2 mg/dL ; Cancer patient receive chemotherapy radiation therapy within past 60 day . Any exposure investigational drug ( ) medical device ( ) within four ( 4 ) week prior image study ; Any physical psychological disease judge investigator incompatible study , base medical history screen physical examination . NYHA Class III IV Congestive heart failure ; Subject symptomatic hypotension Allergic intolerant aminophylline , nitroglycerin metoprolol Allergic intolerant regadenoson excipients Prior participant study . Female subject : Positive serum and/or urine pregnancy test lactate possibility pregnancy rule prior dose . Females childbearing potential require confirmatory documentation medical record must negative pregnancy test within 4 hour prior receive test drug agree use acceptable form birth control least 30 day follow BFPET administration .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
</DOC>